Cardiac biointerventions: Whatever happened to stem cell and gene therapy?

Todd K. Rosengart, Eleanor Fallon, Ronald Crystal

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Angiogenic gene therapy and stem cell administration represent two "biologic" interventions for the treatment of cardiac disease that were first introduced more than 15 years ago but still have not achieved approval for clinical use for the treatment of myocardial ischemia and heart failure. Challenges that have been encountered in the clinical testing of these new treatment strategies have included a lack of placebo controls in phase I surgical trials and the incorporation of potentially ineffectual agent delivery via intracoronary routes. Although enthusiasm for these approaches may therefore have ebbed, new refinements in these technologies and insights into their appropriate clinical testing suggest that a resurgence of interest in these "biointerventions" may be expected in the near future.

Original languageEnglish
Pages (from-to)173-179
Number of pages7
JournalInnovations: Technology and Techniques in Cardiothoracic and Vascular Surgery
Volume7
Issue number3
DOIs
Publication statusPublished - 1 May 2012
Externally publishedYes

Fingerprint

Cell- and Tissue-Based Therapy
Genetic Therapy
Stem Cells
Heart Failure
Myocardial Ischemia
Heart Diseases
Therapeutics
Placebos
Technology

Keywords

  • Angiogenesis
  • Gene therapy
  • Heart failure
  • Stem cells
  • VEGF

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Cardiac biointerventions : Whatever happened to stem cell and gene therapy? / Rosengart, Todd K.; Fallon, Eleanor; Crystal, Ronald.

In: Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, Vol. 7, No. 3, 01.05.2012, p. 173-179.

Research output: Contribution to journalReview article

@article{2f2814b26881472482079e96214cdf5e,
title = "Cardiac biointerventions: Whatever happened to stem cell and gene therapy?",
abstract = "Angiogenic gene therapy and stem cell administration represent two {"}biologic{"} interventions for the treatment of cardiac disease that were first introduced more than 15 years ago but still have not achieved approval for clinical use for the treatment of myocardial ischemia and heart failure. Challenges that have been encountered in the clinical testing of these new treatment strategies have included a lack of placebo controls in phase I surgical trials and the incorporation of potentially ineffectual agent delivery via intracoronary routes. Although enthusiasm for these approaches may therefore have ebbed, new refinements in these technologies and insights into their appropriate clinical testing suggest that a resurgence of interest in these {"}biointerventions{"} may be expected in the near future.",
keywords = "Angiogenesis, Gene therapy, Heart failure, Stem cells, VEGF",
author = "Rosengart, {Todd K.} and Eleanor Fallon and Ronald Crystal",
year = "2012",
month = "5",
day = "1",
doi = "10.1097/IMI.0b013e318265d9f6",
language = "English",
volume = "7",
pages = "173--179",
journal = "Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery",
issn = "1556-9845",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Cardiac biointerventions

T2 - Whatever happened to stem cell and gene therapy?

AU - Rosengart, Todd K.

AU - Fallon, Eleanor

AU - Crystal, Ronald

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Angiogenic gene therapy and stem cell administration represent two "biologic" interventions for the treatment of cardiac disease that were first introduced more than 15 years ago but still have not achieved approval for clinical use for the treatment of myocardial ischemia and heart failure. Challenges that have been encountered in the clinical testing of these new treatment strategies have included a lack of placebo controls in phase I surgical trials and the incorporation of potentially ineffectual agent delivery via intracoronary routes. Although enthusiasm for these approaches may therefore have ebbed, new refinements in these technologies and insights into their appropriate clinical testing suggest that a resurgence of interest in these "biointerventions" may be expected in the near future.

AB - Angiogenic gene therapy and stem cell administration represent two "biologic" interventions for the treatment of cardiac disease that were first introduced more than 15 years ago but still have not achieved approval for clinical use for the treatment of myocardial ischemia and heart failure. Challenges that have been encountered in the clinical testing of these new treatment strategies have included a lack of placebo controls in phase I surgical trials and the incorporation of potentially ineffectual agent delivery via intracoronary routes. Although enthusiasm for these approaches may therefore have ebbed, new refinements in these technologies and insights into their appropriate clinical testing suggest that a resurgence of interest in these "biointerventions" may be expected in the near future.

KW - Angiogenesis

KW - Gene therapy

KW - Heart failure

KW - Stem cells

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84865469024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865469024&partnerID=8YFLogxK

U2 - 10.1097/IMI.0b013e318265d9f6

DO - 10.1097/IMI.0b013e318265d9f6

M3 - Review article

C2 - 22885457

AN - SCOPUS:84865469024

VL - 7

SP - 173

EP - 179

JO - Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery

JF - Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery

SN - 1556-9845

IS - 3

ER -